Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease
Listen to an audio podcast of the March 31, 2021 FDA Drug Safety Communication that FDA review of studies show a potential increased risk of heart rhythm problems, in patients with heart disease taking lamotrigine (Lamictal). FDA requiring studies to evaluate heart risk across the drug class. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - April 2, 2021 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - July 12, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
Lamotrigine versus carbamazepine monotherapy (single medication treatment) for epilepsy
Up to 70 million people worldwide have epilepsy and there are many Cochrane Reviews of ways to treat it. These include reviews that work with the original researchers to gather data on everyone who was in their studies, to perform individual participant data meta-analyses. In June 2018, Sarah Nevitt and colleagues from the University of Liverpool in the UK updated one of these reviews, comparing two commonly used drugs, lamotrigine and carbamazepine. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - December 13, 2018 Category: General Medicine Authors: Cochrane Source Type: podcasts
FDA Drug Safety Podcast: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal)
On April 25, 2018, FDA warned that the medicine lamotrigine (brand name Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body ’s infection-fighting immune system. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - April 30, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Lamotrigine versus carbamazepine monotherapy (single drug treatment) for epilepsy
Up to 70 million people worldwide have epilepsy and there are many Cochrane Reviews of ways to treat it. These include reviews that work with the original researchers to gather data on everyone who was in their studies, to perform individual participant data meta-analyses. In November 2016, Sarah Nolan and colleagues from the University of Liverpool in the UK updated one of these reviews, comparing two commonly used drugs, lamotrigine and carbamazepine. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - April 26, 2017 Category: Journals (General) Authors: Cochrane Source Type: podcasts
